Current Report Filing (8-k)
February 20 2018 - 6:33AM
Edgar (US Regulatory)
UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
FORM
8-K
CURRENT
REPORT
Pursuant to Section 13 or 15(d)
of the Securities Exchange Act of 1934
Date of Report (Date of earliest event reported): February 20, 2018
ACHIEVE LIFE SCIENCES, INC.
(Exact name of Registrant as Specified in Its Charter)
|
|
|
|
|
Delaware
|
|
033-80623
|
|
95-4343413
|
(State or Other Jurisdiction
of Incorporation)
|
|
(Commission
File Number)
|
|
(IRS Employer
Identification No.)
|
|
|
|
1001 W. Broadway, Suite 400
Vancouver, BC
|
|
V6H 4B1
|
(Address of Principal Executive Offices)
|
|
(Zip Code)
|
Registrants Telephone Number, Including Area Code: (604)
736-3678
N/A
(Former Name or Former Address, if Changed Since Last Report)
Check the appropriate box below if the
Form 8-K
filing is intended to simultaneously satisfy the filing
obligation of the registrant under any of the following provisions (see General Instruction A.2. below):
☐
|
Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
|
☐
|
Soliciting material pursuant to
Rule 14a-12
under the Exchange Act (17 CFR
240.14a-12)
|
☐
|
Pre-commencement
communications pursuant to
Rule 14d-2(b)
under the Exchange Act (17 CFR
240.14d-2(b))
|
☐
|
Pre-commencement
communications pursuant to
Rule 13e-4(c)
under the Exchange Act (17 CFR
240.13e-4(c))
|
Indicate by check mark whether the registrant is an emerging growth company as
defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or
Rule 12b-2
of the Securities Exchange Act of 1934
(§240.12b-2
of this
chapter).
Emerging growth company ☐
If
an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange
Act. ☐
Item 7.01
|
Regulation FD Disclosure.
|
A copy of Achieve Life Sciences, Inc.s (the
Company) press release announcing preliminary data from the cytisine Phase I/II multi-dose, pharmacokinetic and pharmacodynamics clinical study and a copy of the Companys related corporate presentation are furnished as Exhibits
99.1 and 99.2, respectively, to this Current Report on Form
8-K.
The information in this
Item 7.01 of Current Report on Form
8-K,
as well as Exhibits 99.1 and 99.2, shall not be treated as filed for purposes of Section 18 of the Securities Exchange Act of 1934, as amended,
nor shall it be deemed incorporated by reference in any filing under the Securities Act of 1933, as amended.
Item 9.01.
|
Financial Statements and Exhibits.
|
(d) Exhibits
SIGNATURES
Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has caused this report to be signed on its behalf by the undersigned,
thereunto duly authorized.
|
|
|
|
|
|
|
|
|
|
|
|
|
ACHIEVE LIFE SCIENCES, INC.
|
|
|
|
|
Date: February 20, 2018
|
|
|
|
|
|
/s/ John Bencich
|
|
|
|
|
|
|
John Bencich
|
|
|
|
|
|
|
Chief Financial and Operating Officer
|
4
Achieve Life Sciences (NASDAQ:ACHV)
Historical Stock Chart
From Aug 2024 to Sep 2024
Achieve Life Sciences (NASDAQ:ACHV)
Historical Stock Chart
From Sep 2023 to Sep 2024